246 related articles for article (PubMed ID: 20308296)
21. A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice.
Morton M; Garmory HS; Perkins SD; O'Dowd AM; Griffin KF; Turner AK; Bennett AM; Titball RW
Vaccine; 2004 Jun; 22(20):2524-32. PubMed ID: 15193377
[TBL] [Abstract][Full Text] [Related]
22. Different strategies for preparation of non-tagged rV270 protein and its efficacy against Yersinia pestis challenge.
Wang W; Qi ZZ; Zhang QW; Wu BC; Zhu ZW; Yang YH; Cui BZ; Dai RX; Qiu YF; Wang ZY; Guo ZB; Shi TX; Wang H; Yang RF; Wang XY
Biomed Environ Sci; 2010 Oct; 23(5):333-40. PubMed ID: 21112480
[TBL] [Abstract][Full Text] [Related]
23. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.
Wang S; Heilman D; Liu F; Giehl T; Joshi S; Huang X; Chou TH; Goguen J; Lu S
Vaccine; 2004 Sep; 22(25-26):3348-57. PubMed ID: 15308359
[TBL] [Abstract][Full Text] [Related]
24. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.
Boyer JL; Sofer-Podesta C; Ang J; Hackett NR; Chiuchiolo MJ; Senina S; Perlin D; Crystal RG
Hum Gene Ther; 2010 Jul; 21(7):891-901. PubMed ID: 20180652
[TBL] [Abstract][Full Text] [Related]
25. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague.
Do Y; Koh H; Park CG; Dudziak D; Seo P; Mehandru S; Choi JH; Cheong C; Park S; Perlin DS; Powell BS; Steinman RM
Eur J Immunol; 2010 Oct; 40(10):2791-6. PubMed ID: 20812236
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge.
Sofer-Podesta C; Ang J; Hackett NR; Senina S; Perlin D; Crystal RG; Boyer JL
Infect Immun; 2009 Apr; 77(4):1561-8. PubMed ID: 19124600
[TBL] [Abstract][Full Text] [Related]
27. Induction of Protective Antiplague Immune Responses by Self-Adjuvanting Bionanoparticles Derived from Engineered Yersinia pestis.
Wang X; Singh AK; Zhang X; Sun W
Infect Immun; 2020 Apr; 88(5):. PubMed ID: 32152195
[TBL] [Abstract][Full Text] [Related]
28. LcrV plague vaccine with altered immunomodulatory properties.
Overheim KA; Depaolo RW; Debord KL; Morrin EM; Anderson DM; Green NM; Brubaker RR; Jabri B; Schneewind O
Infect Immun; 2005 Aug; 73(8):5152-9. PubMed ID: 16041032
[TBL] [Abstract][Full Text] [Related]
29. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
[No Abstract] [Full Text] [Related]
30. Yersinia pestis caf1 variants and the limits of plague vaccine protection.
Quenee LE; Cornelius CA; Ciletti NA; Elli D; Schneewind O
Infect Immun; 2008 May; 76(5):2025-36. PubMed ID: 18347051
[TBL] [Abstract][Full Text] [Related]
31. Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates.
Sizemore DR; Warner EA; Lawrence JA; Thomas LJ; Roland KL; Killeen KP
Hum Vaccin Immunother; 2012 Mar; 8(3):371-83. PubMed ID: 22327496
[TBL] [Abstract][Full Text] [Related]
32. A live attenuated strain of Yersinia pestis KIM as a vaccine against plague.
Sun W; Six D; Kuang X; Roland KL; Raetz CR; Curtiss R
Vaccine; 2011 Apr; 29(16):2986-98. PubMed ID: 21320544
[TBL] [Abstract][Full Text] [Related]
33. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
[TBL] [Abstract][Full Text] [Related]
34. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague.
Titball RW; Howells AM; Oyston PC; Williamson ED
Infect Immun; 1997 May; 65(5):1926-30. PubMed ID: 9125581
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the humoral immune response in mice orally vaccinated with live recombinant attenuated Salmonella enterica delivering a secreted form of Yersinia pestis PsaA.
Torres-Escobar A; Juárez-Rodríguez MD; Branger CG; Curtiss R
Vaccine; 2010 Aug; 28(36):5810-6. PubMed ID: 20600475
[TBL] [Abstract][Full Text] [Related]
36. Expression of Yersinia pestis V antigen in attenuated salmonella typhimurium: development of a novel vaccine for plague.
Leary SE; Eley SM; Williamson ED; Titball RW
Contrib Microbiol Immunol; 1995; 13():216-7. PubMed ID: 8833838
[No Abstract] [Full Text] [Related]
37. Polymorphism in the
Daniel C; Dewitte A; Poiret S; Marceau M; Simonet M; Marceau L; Descombes G; Boutillier D; Bennaceur N; Bontemps-Gallo S; Lemaître N; Sebbane F
Front Immunol; 2019; 10():1830. PubMed ID: 31428104
[TBL] [Abstract][Full Text] [Related]
38. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen.
Chiuchiolo MJ; Boyer JL; Krause A; Senina S; Hackett NR; Crystal RG
J Infect Dis; 2006 Nov; 194(9):1249-57. PubMed ID: 17041851
[TBL] [Abstract][Full Text] [Related]
39. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.
Chattopadhyay A; Park S; Delmas G; Suresh R; Senina S; Perlin DS; Rose JK
Vaccine; 2008 Nov; 26(50):6329-37. PubMed ID: 18832004
[TBL] [Abstract][Full Text] [Related]
40. Regulated Delayed
Su H; Liu Q; Wang S; Curtiss R; Kong Q
Theranostics; 2019; 9(12):3565-3579. PubMed ID: 31281498
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
